BAY43-9006 - Phase II in Advanced Breast Cancer
The purpose of this study is to evaluate the anti-cancer activity and safety of BAY43-9006 (Sorafenib) in patients, who suffer from an advanced breast tumour, which has spread to other organs of body despite treatment that the patient has received so far.
Breast Neoplasms|Breast Cancer
DRUG: Sorafenib (Nexavar, BAY43-9006)
Number of Subjects With Response (Complete or Partial), Number of subjects with metastatic breast cancer treated with single agent BAY43-9006 who had best overall response assessed as complete response (CR) or partial response (PR) as per Modified World Health Organization (WHO) Tumor Response Criteria., Until 30 days after termination of active therapy
Time to Progression, Time from start of treatment until progression was first documented., Until progression occurs|Time to Objective Response, Defined only for subjects achieving objective tumor response from start of treatment to the date when confirmed PR or CR was first documented according to the Modified WHO Tumor Response Criteria., Until objective response occurs|Overall Response Duration, Overall response duration was defined only for subjects achieving confirmed objective response (PR or CR). It was measured from start of treatment to the date when progressive disease was first objectively documented., Time from PR or CR to progression|Survival Time, After the end of treatment visit (30 days after the last dose), the subjects were monitored every 3 months for survival (visits/phone calls)., Start of treatment to death|Number of Subjects With Stable Disease up to Cycle 4, Number of subjects who had not responded to treatment but had stable disease up to cycle 4., Until 30 days after termination of active therapy
The purpose of this study is to evaluate the anti-cancer activity and safety of BAY43-9006 (Sorafenib) in patients, who suffer from an advanced breast tumour, which has spread to other organs of body despite treatment that the patient has received so far.